VYGR - Voyager Therapeutics, Inc.
IEX Last Trade
5.69
0.010 0.176%
Share volume: 6,929
Last Updated: Fri 27 Dec 2024 08:30:02 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$5.68
0.01
0.18%
Fundamental analysis
25%
Profitability
25%
Dept financing
10%
Liquidity
75%
Performance
15%
Performance
5 Days
3.14%
1 Month
2.25%
3 Months
1.03%
6 Months
-24.81%
1 Year
-32.07%
2 Year
9.24%
Key data
Stock price
$5.69
DAY RANGE
$5.61 - $5.92
52 WEEK RANGE
$5.38 - $11.72
52 WEEK CHANGE
-$29.98
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Alfred W. Sandrock
Region: US
Website: voyagertherapeutics.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: voyagertherapeutics.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease.
Recent news